Description

Fresenius Medical Care Faces A 0.37% Volume Warning In U.S. Dialysis?

Fresenius Medical Care reported steady operational and financial performance in the first quarter of 2026, with organic revenue growth of 4%, supported across all three segments: Care Delivery, Value-Based Care, and Care Enablement. At constant currency, revenues increased by 3%. Operating income advanced by 10%, reflecting margin expansion to 10.1%, aligning with management’s anticipated phasing for the year. These results were supported by the continued execution of the FME25+ cost-saving program, which contributed EUR 50 million in sustainable savings, and an accelerated share buyback completed ahead of schedule, reducing shares by 8.5% and maintaining net leverage at 2.6x within the lower end of the target corridor. The Care Delivery segment saw organic revenue growth of 6%, bolstered by gains in the U.S. market influenced by new TDAPA reimbursement regulations and favorable payer mix, despite a 0.